UTILITY OF PET USING 18FLUORO-3-DEOXY-L-FLUOROTHYMIDINE (FLT-PET) IN LYMPHOMA

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The term functional imaging refers to technology that allows imaging not based on sizes and shapes of tissues and organs, as in CT scanning, but rather based on functional properties of the cells in these tissues. For example, positron emission tomography (PET) using 18-fluoro-2-deoxyglucose (FDG) images tissues based on metabolism, with high uptake of tracer in cells that metabolize glucose at a high rate. FDG-PET is useful in the care of patients with many cancers, including lymphoma. However, it presents drawbacks in some specific situations, such as determining grade, or aggressiveness, of lymphoma, as well as differentiating lymphoma from non-cancerous lesions such as infection or inflammation. 18-fluoro-3'-deoxy-3'-L-fluorothymidine (FLT) is a new tracer which is taken up by actively dividing cells. It has been suggested that FLT might be better in determining grade and differentiating cancer from inflammation than is FDG. We propose a pilot study to look at the characteristics of FLT-PET imaging in patients with various types of lymphoma. Our objectives include a) to determine whether FLT-PET scanning detects cancerous lesions in patients with various types of lymphoma, b) to determine intensity of FLT uptake as determined by PET and whether it correlates with lymphoma grade, and c) to compare FLT-PET to FDG-PET in detection of cancerous lesions in diverse types of lymphoma.'